To verify the hypothesis, we retrospectively collected a cohort of 261 CRC samples harboring BRAF mutation and divided them into two groups: 174 patients in the RNF43 wild-type group and 87 patients in the RNF43 mutant group (Supplementary Table 1). Here, RNF43 is linked to colorectal carcinoma.